HRP20211152T1 - Konjugati antitijela s lijekom koji ciljaju na uparap - Google Patents

Konjugati antitijela s lijekom koji ciljaju na uparap Download PDF

Info

Publication number
HRP20211152T1
HRP20211152T1 HRP20211152TT HRP20211152T HRP20211152T1 HR P20211152 T1 HRP20211152 T1 HR P20211152T1 HR P20211152T T HRP20211152T T HR P20211152TT HR P20211152 T HRP20211152 T HR P20211152T HR P20211152 T1 HRP20211152 T1 HR P20211152T1
Authority
HR
Croatia
Prior art keywords
antibody
drug conjugate
fragment
binds
antigen
Prior art date
Application number
HRP20211152TT
Other languages
English (en)
Inventor
Christoffer NIELSEN
Niels Behrendt
Lars Henning ENGELHOLM
Original Assignee
Rigshospitalet
University Of Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet, University Of Copenhagen filed Critical Rigshospitalet
Publication of HRP20211152T1 publication Critical patent/HRP20211152T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (20)

1. Konjugat antitijela s lijekom usmjeren protiv uPARAP, koji sadrži: a) antitijelo koje se veže na aminokiselinski slijed SEQ ID NO: 32 ili 33 (fibronektinska domena tipa II (FN-II) u uPARAP), b) aktivno sredstvo, gdje se aktivno sredstvo bira između terapijskog sredstva, citotoksičnog sredstva, radioizotopa i biljega kojeg se može detektirati, i c) spojnicu koja spaja a) s b).
2. Konjugat antitijela s lijekom u skladu s patentnim zahtjevom 1, gdje se antitijelo bira iz skupine koju čine: a) antitijelo, ili njegov fragment koji se veže na antigen, koje sadrži i. varijabilno područje lakog lanca imunoglobulina koje sadrži ili se sastoji od aminokiselinskog slijeda SEQ ID NO: 11 ili slijed koji mu je istovjetan po slijedu najmanje 90 %, i ii. varijabilno područje teškog lanca imunoglobulina koje sadrži ili se sastoji od aminokiselinskog slijeda SEQ ID NO: 15 ili slijed koji mu je istovjetan po slijedu najmanje 90 %, gdje se bilo koja varijanca slijeda nalazi izvan područja određivanja komplementarnosti, b) humanizirana verzija antitijela, ili njegovog fragmenta koji se veže na antigen, iz a), c) kimerna verzija antitijela, ili njegovog fragmenta koji se veže na antigen, iz a), d) antitijelo, ili njegov fragment koji se veže na antigen, koje sadrži i. varijabilno područje lakog lanca imunoglobulina koje sadrži aminokiselinske sljedove SEQ ID NO: 12, 13 i 14, i ii. varijabilno područje teškog lanca imunoglobulina koje sadrži aminokiselinske sljedove SEQ ID NO 16, 17 i 18, e) antitijelo, ili njegov fragment koji se veže na antigen, koje sadrži i. varijabilno područje lakog lanca imunoglobulina koje sadrži aminokiselinske sljedove SEQ ID NO: 48, 49 i 50, i ii. varijabilno područje teškog lanca imunoglobulina koje sadrži aminokiselinske sljedove SEQ ID NO 51, 52 i 53, f) humanizirana verzija antitijela, ili njegovog fragmenta koji se veže na antigen, iz d) ili e).
3. Konjugat antitijela s lijekom u skladu s patentnim zahtjevom 1, gdje se antitijelo bira iz skupine koju čine: a) antitijelo, ili njegov fragment koji se veže na antigen, koje sadrži i. varijabilno područje lakog lanca imunoglobulina koje sadrži ili se sastoji od aminokiselinskog slijeda SEQ ID NO: 19 ili 20 ili slijed koji mu je istovjetan po slijedu najmanje 90 %, i ii. varijabilno područje teškog lanca imunoglobulina koje sadrži ili se sastoji od aminokiselinskog slijeda SEQ ID NO: 24 ili 25 ili slijed koji mu je istovjetan po slijedu najmanje 90 %, gdje se bilo koja varijanca slijeda nalazi izvan područja određivanja komplementarnosti, b) humanizirana verzija antitijela, ili njegovog fragmenta koji se veže na antigen, iz a), c) kimerna verzija antitijela, ili njegovog fragmenta koji se veže na antigen, iz a), d) antitijelo, ili njegov fragment koji se veže na antigen, koje sadrži i. varijabilno područje lakog lanca imunoglobulina koje sadrži aminokiselinske sljedove SEQ ID NO: 21, 22 i 23, i ii. varijabilno područje teškog lanca imunoglobulina koje sadrži aminokiselinske sljedove SEQ ID NO 26, 27 i 28, e) antitijelo, ili njegov fragment koji se veže na antigen, koje sadrži i. varijabilno područje lakog lanca imunoglobulina koje sadrži aminokiselinske sljedove SEQ ID NO: 54, 55 i 56, i ii. varijabilno područje teškog lanca imunoglobulina koje sadrži aminokiselinske sljedove SEQ ID NO 57, 58 i 59, f) humanizirana verzija antitijela, ili njegovog fragmenta koji se veže na antigen, iz d) ili e).
4. Konjugat antitijela s lijekom u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje se antitijelo bira između mišjeg antitijela, kimernog antitijela, ljudskog antitijela, humaniziranog antitijela, humanizirani fragment koji se veže na antigen, Fab fragmenta, Fab’ fragmenta, F(ab’)2 fragmenta, Fv, jednolančano antitijelo (SCA), poput scFv, varijabilnog dijela njegovih teških i/ili lakih lanaca, te Fab miniantitijela.
5. Konjugat antitijela s lijekom u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje je antitijelo monoklonsko antitijelo.
6. Konjugat antitijela s lijekom u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje je aktivno sredstvo kemoterapijsko sredstvo, poput kemoterapijskog sredstva kojeg se bira iz skupine koju čine alkilirajuća sredstva, antraciklini, antimetaboliti, sredstva protiv mikrotubula/protumitotska sredstva, inhibitori histonske deacetilaze, inhibitori kinaza, peptidni antibiotici, antineoplastična sredstva na bazi platine, inhibitori topoizomeraze i citotoksični antibiotici.
7. Konjugat antitijela s lijekom u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje je aktivno sredstvo protumitotsko sredstvo, kojeg se primjerice bira iz skupine koju čine monometilirani auristatin E (MMAE), monometilirani auristatin F (MMAF), taksan (primjerice paklitaksel ili docetaksel), vinka alkaloid (primjerice vinblastin, vinkristin, vindezin ili vinorelbin), kolhicin ili podofilotoksin.
8. Konjugat antitijela s lijekom u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje je aktivno sredstvo sredstvo za umrežavanje DNA, poput sredstva za umrežavanje DNA kojeg se bira između pirolobenzodiazepina ili dimernog derivata pirolobenzodiazepina.
9. Konjugat antitijela s lijekom u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje je aktivno sredstvo alkilirajuće sredstvo, poput duokarmicina SA.
10. Konjugat antitijela s lijekom u skladu s bilo kojim od prethodnih patentnih zahtjeva namijenjen upotrebi kao medikament.
11. Farmaceutski pripravak koji sadrži konjugat antitijela s lijekom u skladu s bilo kojim od patentnih zahtjeva 1 do 9, te farmaceutski prihvatljivi pufer, razrjeđivač, nosač, adjuvans ili pomoćno sredstvo.
12. Konjugat antitijela s lijekom u skladu s bilo kojim od patentnih zahtjeva 1 do 9 ili farmaceutski pripravak u skladu s patentnim zahtjevom 11, namijenjen upotrebi u postupku liječenja bolesti naznačene time što su prisutne stanice koje eksprimiraju uPARAP, primjerice gdje se bolest naznačena time što su prisutne stanice koje eksprimiraju uPARAP bira između raka, bolesti propadanja kostiju poput osteoporoze, fibroze, te bolesti ili poremećaji povezani s makrofazima poput ateroskleroze ili kronične upale.
13. Konjugat antitijela s lijekom ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 12, gdje je bolest rak.
14. Konjugat antitijela s lijekom ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 13, gdje je rak sarkom, poput osteosarkoma, liposarkoma, miksofibrosarkoma, protuberantnog dermatofibrosarkoma (DFSP) i/ili lejomiosarkoma (LMS).
15. Konjugat antitijela s lijekom ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 13, gdje je rak glioblastom.
16. Konjugat antitijela s lijekom ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 13, gdje je rak rak prostate ili metastaze na kostima iz raka prostate.
17. Konjugat antitijela s lijekom ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 13, gdje je rak rak dojke.
18. Konjugat antitijela s lijekom ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 13, gdje je rak rak glave i vrata.
19. Konjugat antitijela s lijekom ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 13, gdje je rak leukemija.
20. Komplet koji sadrži konjugat antitijela s lijekom u skladu s bilo kojim od patentnih zahtjeva 1 do 9 ili farmaceutski pripravak u skladu s patentnim zahtjevom 11, koji može dodatno sadržavati sredstvo za primjenu konjugata antitijela s lijekom na subjektu i/ili upute o upotrebi.
HRP20211152TT 2016-02-05 2021-07-19 Konjugati antitijela s lijekom koji ciljaju na uparap HRP20211152T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201670063 2016-02-05
DKPA201670834 2016-10-24
PCT/DK2017/050024 WO2017133745A1 (en) 2016-02-05 2017-02-03 ANTIBODY-DRUG CONJUGATES TARGETING uPARAP
EP17706673.5A EP3411076B1 (en) 2016-02-05 2017-02-03 Antibody-drug conjugates targeting uparap

Publications (1)

Publication Number Publication Date
HRP20211152T1 true HRP20211152T1 (hr) 2021-10-15

Family

ID=58108381

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20230505TT HRP20230505T1 (hr) 2016-02-05 2017-02-03 Konjugati antitijela s lijekom koji ciljaju na uparap
HRP20211152TT HRP20211152T1 (hr) 2016-02-05 2021-07-19 Konjugati antitijela s lijekom koji ciljaju na uparap

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20230505TT HRP20230505T1 (hr) 2016-02-05 2017-02-03 Konjugati antitijela s lijekom koji ciljaju na uparap

Country Status (23)

Country Link
US (3) US10940213B2 (hr)
EP (2) EP3895736B1 (hr)
JP (2) JP7125059B2 (hr)
KR (1) KR20180105155A (hr)
CN (1) CN108883197B (hr)
AU (1) AU2017215869B2 (hr)
BR (1) BR112018015448A2 (hr)
CA (1) CA3013677A1 (hr)
CY (2) CY1124280T1 (hr)
DK (2) DK3895736T3 (hr)
ES (2) ES2874668T3 (hr)
FI (1) FI3895736T3 (hr)
HK (1) HK1258338A1 (hr)
HR (2) HRP20230505T1 (hr)
HU (2) HUE054938T2 (hr)
LT (2) LT3411076T (hr)
MX (2) MX2018009461A (hr)
PL (2) PL3411076T3 (hr)
PT (2) PT3895736T (hr)
RS (2) RS62115B1 (hr)
RU (1) RU2740311C2 (hr)
SI (2) SI3895736T1 (hr)
WO (1) WO2017133745A1 (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3013677A1 (en) 2016-02-05 2017-08-10 Rigshospitalet Antibody-drug conjugates targeting uparap
IL309336A (en) * 2021-06-29 2024-02-01 Rigshospitalet Antibody-drug conjugates comprising humanized antibodies targeting urokinase-type plasminogen activator receptor-related protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
JP2004137151A (ja) 2002-10-15 2004-05-13 Keio Gijuku 脳腫瘍の治療・診断薬
EP2411413B1 (en) * 2009-03-23 2016-05-11 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
US20150216998A1 (en) * 2012-01-01 2015-08-06 Ramot At Tel-Aviv University Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
RU2530553C2 (ru) * 2012-11-07 2014-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Рекомбинантное однодоменное антитело, способное специфически связывать фактор некроза опухолей человека, и его производные
CA3013677A1 (en) 2016-02-05 2017-08-10 Rigshospitalet Antibody-drug conjugates targeting uparap

Also Published As

Publication number Publication date
EP3895736B1 (en) 2023-04-19
PL3895736T3 (pl) 2023-07-24
RU2740311C2 (ru) 2021-01-13
EP3411076A1 (en) 2018-12-12
LT3895736T (lt) 2023-06-12
MX2022014231A (es) 2022-12-07
SI3895736T1 (sl) 2023-07-31
JP2019511205A (ja) 2019-04-25
US10940213B2 (en) 2021-03-09
WO2017133745A1 (en) 2017-08-10
JP7125059B2 (ja) 2022-08-24
US20210162062A1 (en) 2021-06-03
KR20180105155A (ko) 2018-09-27
LT3411076T (lt) 2021-07-26
PT3411076T (pt) 2021-06-17
JP2022064906A (ja) 2022-04-26
CN108883197B (zh) 2022-05-10
PL3411076T3 (pl) 2021-11-02
CY1124280T1 (el) 2022-07-22
EP3411076B1 (en) 2021-04-28
RU2018125309A3 (hr) 2020-04-27
DK3895736T3 (da) 2023-07-24
HUE061880T2 (hu) 2023-08-28
US20240131179A1 (en) 2024-04-25
US20190046658A1 (en) 2019-02-14
AU2017215869A1 (en) 2018-07-19
MX2018009461A (es) 2018-12-11
JP7304595B2 (ja) 2023-07-07
AU2017215869B2 (en) 2024-02-01
FI3895736T3 (fi) 2023-06-26
HK1258338A1 (zh) 2019-11-08
ES2874668T3 (es) 2021-11-05
HUE054938T2 (hu) 2021-10-28
RU2018125309A (ru) 2020-03-06
ES2946073T3 (es) 2023-07-12
CY1126032T1 (el) 2023-11-15
RS62115B1 (sr) 2021-08-31
PT3895736T (pt) 2023-06-02
CN108883197A (zh) 2018-11-23
RS64219B1 (sr) 2023-06-30
EP3895736A1 (en) 2021-10-20
DK3411076T3 (da) 2021-07-26
US11819552B2 (en) 2023-11-21
SI3411076T1 (sl) 2021-09-30
BR112018015448A2 (pt) 2018-12-18
CA3013677A1 (en) 2017-08-10
HRP20230505T1 (hr) 2023-08-04

Similar Documents

Publication Publication Date Title
CN110869393B (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
ES2796698T3 (es) Anticuerpos anti-CD166 activables y procedimientos de uso de los mismos
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
JP6333882B2 (ja) 抗体−薬剤コンジュゲート
HRP20171789T1 (hr) Konjugati humanog protutijela s lijekom protiv tkivnog faktora
ES2859648T3 (es) Conjugado anticuerpo-fármaco anti-HER3
TWI671317B (zh) 抗ｃｘｃｒ４抗體及抗體-藥物結合物
ES2701051T3 (es) Conjugados de anticuerpo-fármaco
HRP20181646T2 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
TW201920286A (zh) Bcma單株抗體-藥物結合物
HRP20211152T1 (hr) Konjugati antitijela s lijekom koji ciljaju na uparap
JP2022037244A (ja) 抗体３ｅ１０の多価フラグメントおよびその使用方法
CN110248963B (zh) 抗ccr7抗体药物缀合物
JP2017534254A5 (hr)
HRP20231609T1 (hr) Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2
TW201116300A (en) DR5 Ligand Drug Conjugates
RU2020124944A (ru) Антитела против egfr и конъюгаты антитело-лекарственное средство
TW201803599A (zh) 靶向ＮａＰｉ２ｂ之抗體－藥物共軛體類和使用彼等之方法
PT2269656E (pt) Anticorpos selecionados e peptídeos de duramicina que se ligam a fosfolipídios aniônicos e aminofosfolipídios e seus usos no tratamento de infecções virais e câncer
BR112020002368A2 (pt) conjugados anticorpo-medicamento tendo alta tolerabilidade in vivo
JP2015534577A5 (hr)
FI3218005T3 (fi) Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
JP2020502271A (ja) 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
KR20210042120A (ko) 항체-약물 콘주게이트와 튜불린 저해제의 조합
JP2020502271A5 (hr)